Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in m… Read more
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) - Net Assets
Latest net assets as of September 2025: $1.93 Billion USD
Based on the latest financial reports, Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) has net assets worth $1.93 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.30 Billion) and total liabilities ($3.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.93 Billion |
| % of Total Assets | 36.38% |
| Annual Growth Rate | 9.37% |
| 5-Year Change | 47.06% |
| 10-Year Change | N/A |
| Growth Volatility | 2.0 |
Recordati Industria Chimica e Farmaceutica S.p.A. - Net Assets Trend (2019–2024)
This chart illustrates how Recordati Industria Chimica e Farmaceutica S.p.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Recordati Industria Chimica e Farmaceutica S.p.A. (2019–2024)
The table below shows the annual net assets of Recordati Industria Chimica e Farmaceutica S.p.A. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.88 Billion | +11.29% |
| 2023-12-31 | $1.69 Billion | +9.06% |
| 2022-12-31 | $1.55 Billion | +11.92% |
| 2021-12-31 | $1.38 Billion | +8.26% |
| 2020-12-31 | $1.28 Billion | +6.46% |
| 2019-12-31 | $1.20 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Recordati Industria Chimica e Farmaceutica S.p.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 63.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.23 Billion | 119.06% |
| Total Equity | $1.88 Billion | 100.00% |
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors by Market Cap
The table below lists competitors of Recordati Industria Chimica e Farmaceutica S.p.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CES ENERGY SOLUTIONS
F:7C4
|
$1.57 Billion |
|
Mitie Group plc
PINK:MITFF
|
$1.57 Billion |
|
V2X INC. DL-01
F:1V1
|
$1.57 Billion |
|
Hang Zhou Iron & Steel Co Ltd
SHG:600126
|
$1.57 Billion |
|
Zhefu Holding Group Co Ltd
SHE:002266
|
$1.57 Billion |
|
HAZAMA ANDO CORP.
F:2PW
|
$1.57 Billion |
|
Hella KGaA Hueck & Co
XETRA:HLE
|
$1.56 Billion |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
$1.56 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Recordati Industria Chimica e Farmaceutica S.p.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,686,392,000 to 1,876,809,000, a change of 190,417,000 (11.3%).
- Net income of 416,508,000 contributed positively to equity growth.
- Dividend payments of 253,718,000 reduced retained earnings.
- Share repurchases of 119,023,000 reduced equity.
- New share issuances of 92,670,000 increased equity.
- Other factors increased equity by 53,980,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $416.51 Million | +22.19% |
| Dividends Paid | $253.72 Million | -13.52% |
| Share Repurchases | $119.02 Million | -6.34% |
| Share Issuances | $92.67 Million | +4.94% |
| Other Changes | $53.98 Million | +2.88% |
| Total Change | $- | 11.29% |
Book Value vs Market Value Analysis
This analysis compares Recordati Industria Chimica e Farmaceutica S.p.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.47x to 1.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $5.82 | $14.41 | x |
| 2020-12-31 | $6.19 | $14.41 | x |
| 2021-12-31 | $6.71 | $14.41 | x |
| 2022-12-31 | $7.53 | $14.41 | x |
| 2023-12-31 | $8.19 | $14.41 | x |
| 2024-12-31 | $9.10 | $14.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Recordati Industria Chimica e Farmaceutica S.p.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.19%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.79%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 2.74x
- Recent ROE (22.19%) is below the historical average (25.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 30.77% | 24.89% | 0.53x | 2.34x | $248.97 Million |
| 2020 | 27.82% | 24.50% | 0.53x | 2.13x | $227.39 Million |
| 2021 | 27.94% | 24.43% | 0.56x | 2.04x | $247.80 Million |
| 2022 | 20.20% | 16.85% | 0.46x | 2.59x | $157.71 Million |
| 2023 | 23.08% | 18.69% | 0.49x | 2.50x | $220.57 Million |
| 2024 | 22.19% | 17.79% | 0.46x | 2.74x | $228.83 Million |
Industry Comparison
This section compares Recordati Industria Chimica e Farmaceutica S.p.A.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) | $1.93 Billion | 30.77% | 1.75x | $1.57 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |